Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.

Scartozzi, M. et al. (2006) Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori, 92(5), pp. 384-388. (doi: 10.1177/030089160609200503) (PMID:17168429)

Full text not currently available from Enlighten.

Abstract

Aims and Background: We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy. Methods: Patients with advanced colorectal cancer undergoing third-line chemotherapy after failure of 5-FU with CPT-11 or oxaliplatin-based chemotherapy regimens were treated with capecitabine and mitomycin C. Results: Sixty-one patients were enrolled in this study. The median age was 55 years (range, 26-78 years) and the male:female ratio 21: 40. We observed partial remissions in 5 patients (8%), stable disease in 25 patients (40%) and progression of disease in 31 patients (52%). Median TTP was 3 months and median survival was 6 months. Global toxicity was mild and entirely acceptable. Grade 3-4 hematological toxicity occurred in 12 patients and grade 3-4 nonhematological toxicity in 5 patients. Conclusions: The combination of capecitabine and mitomycin C could represent an effective and manageable treatment option for colorectal cancer patients failing previous chemotherapy regimens.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Braconi, Professor Chiara
Authors: Scartozzi, M., Falcone, A., Pucci, F., Braconi, C., Pleratoni, C., Cavanna, L., Franciosi, V., Berardi, R., Beretta, G., Masi, G., Allegrini, G., Zaniboni, A., Lablanca, R., and Cascinu, S.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Tumori
Publisher:SAGE Publications
ISSN:0300-8916
ISSN (Online):2038-2529

University Staff: Request a correction | Enlighten Editors: Update this record